
  
    
      
        Background_NNP
        Atrial_NNP fibrillation_NN is_VBZ thought_VBN to_TO be_VB more_RBR common_JJ in_IN
        chronic_JJ dialysis_NN patients_NNS than_IN in_IN the_DT general_JJ population_NN ,_,
        although_IN population_NN based_VBD comparisons_NNS are_VBP not_RB available_JJ ._. [_NN
        1_CD ]_NN Atrial_NNP fibrillation_NN is_VBZ worthy_JJ of_IN separate_JJ study_NN from_IN
        other_JJ dysrythmias_NNS due_JJ to_TO unique_JJ aspects_NNS of_IN its_PRP$ natural_JJ
        history_NN and_CC management_NN ._. [_NN 1_CD ]_NN Risk_NN factors_NNS for_IN atrial_NN
        fibrillation_NN may_MD be_VB more_RBR common_JJ in_IN dialysis_NN ,_, and_CC include_VBP
        age_NN ,_, cardiac_JJ enlargement_NN and_CC an_DT abnormal_JJ
        calcium-phosphorous_JJ metabolism_NN ._. [_NN 2_CD 3_CD 4_CD 5_CD ]_NN However_RB ,_, the_DT
        incidence_NN ,_, risk_NN factors_NNS and_CC associated_VBN mortality_NN for_IN
        hospitalized_VBN atrial_NN fibrillation_NN have_VBP not_RB been_VBN reported_VBN for_IN
        a_DT national_JJ population_NN of_IN chronic_JJ dialysis_NN patients_NNS ._.
        Previous_JJ studies_NNS have_VBP also_RB not_RB assessed_VBN the_DT effects_NNS of_IN
        cardioprotective_JJ medications_NNS on_IN atrial_NN fibrillation_NN in_IN
        dialysis_NN patients_NNS ._. The_DT management_NN of_IN chronic_JJ dialysis_NN
        patients_NNS with_IN atrial_NN fibrillation_NN is_VBZ controversial_JJ ,_, since_IN
        studies_NNS of_IN atrial_NN fibrillation_NN have_VBP generally_RB excluded_VBN
        patients_NNS with_IN chronic_JJ renal_JJ failure_NN ._. [_NN 6_CD 7_CD ]_NN We_PRP therefore_RB
        performed_VBD an_DT historical_JJ cohort_NN study_NN of_IN the_DT United_NNP States_NNPS
        Renal_NNP Data_NNP System_NNP (_( USRDS_NNP )_) Dialysis_NNP Morbidity_NNP and_CC Mortality_NNP
        Study_NNP (_( DMMS_NNP )_) Wave_NNP 2_CD ,_, which_WDT includes_VBZ information_NN on_IN blood_NN
        pressure_NN ,_, lipid_NN levels_NNS ,_, medications_NNS ,_, and_CC other_JJ important_JJ
        clinical_JJ data_NNS ._. Our_PRP$ objectives_NNS were_VBD to_TO determine_VB the_DT
        incidence_NN ,_, and_CC risk_NN factors_NNS for_IN hospitalized_VBN atrial_NN
        fibrillation_NN (_( primary_JJ hospitalization_NN discharge_NN ICD_NNP 9_CD code_NN
        427_CD ._. 31_CD ._. x_SYM )_) ,_, occurring_VBG after_IN the_DT initiation_NN of_IN dialysis_NN but_CC
        prior_RB to_TO receipt_NN of_IN renal_JJ transplantation_NN ,_, as_RB well_RB as_IN
        determine_VB risk_NN factors_NNS for_IN mortality_NN after_IN hospitalized_VBN
        atrial_NN fibrillation_NN ._.
      
      
        Methods_NNP
        
          Statistical_NNP analysis_NN
          Univariate_NNP analysis_NN was_VBD performed_VBN with_IN Chi-_NNP Square_NNP
          testing_NN for_IN categorical_JJ variables_NNS (_( Fisher_NNP exact_JJ test_NN used_VBN
          for_IN violations_NNS of_IN Cochran_NNP 's_POS assumptions_NNS )_) and_CC student_NN 's_POS
          t-test_JJ for_IN continuous_JJ variables_NNS (_( Mann_NNP Whitney_NNP test_NN was_VBD
          used_VBN for_IN variables_NNS without_IN a_DT Gaussian_NNP distribution_NN )_) ._.
          Variables_NNP with_IN borderline_NN significance_NN (_( p_NN value_NN <_NN 0_CD ._. 1_CD
          in_IN univariate_NN analysis_NN )_) and_CC those_DT thought_VBD likely_JJ to_TO have_VB
          a_DT clinical_JJ relationship_NN with_IN atrial_NN fibrillation_NN ,_, such_JJ as_IN
          cardioprotective_JJ medications_NNS and_CC blood_NN pressure_NN ,_, were_VBD
          entered_VBN into_IN the_DT multivariate_NN models_NNS ._. In_IN addition_NN ,_,
          variables_NNS thought_VBD to_TO have_VB a_DT likely_JJ clinical_JJ relationship_NN
          with_IN atrial_NN fibrillation_NN were_VBD also_RB entered_VBN into_IN the_DT
          multivariate_NN model_NN ,_, in_IN accordance_NN with_IN established_VBN
          epidemiological_JJ principles_NNS ._. [_NN 17_CD ]_NN Stepwise_NNP (_( forward_RB
          likelihood_NN ratio_NN method_NN )_) Cox_NNP proportional_JJ hazards_NNS
          analysis_NN was_VBD used_VBN to_TO assess_VB the_DT association_NN between_IN
          baseline_NN factors_NNS and_CC hospitalized_VBN atrial_NN fibrillation_NN ,_,
          independent_JJ of_IN other_JJ factors_NNS ._. Log-log_NNP plots_NNS were_VBD
          inspected_VBN to_TO verify_VB the_DT existence_NN of_IN proportional_JJ
          hazards_NNS ._. Estimated_VBN hazard_NN ratios_NNS (_( HR_NNP )_) along_IN with_IN
          corresponding_JJ 95_CD %_NN confidence_NN intervals_NNS (_( CI_NNP )_) and_CC p_NN values_NNS
          are_VBP reported_VBN for_IN all_DT regression_NN covariates_NNS ._. Stepwise_NNP
          logistic_JJ regression_NN was_VBD used_VBN to_TO test_VB the_DT independent_JJ
          association_NN of_IN patient_NN factors_NNS with_IN preexisting_VBG coumadin_NN
          and_CC cardioselective_JJ beta-blocker_NN use_NN ,_, using_VBG the_DT same_JJ
          covariates_NNS as_IN Cox_NNP Regression_NNP above_IN ._. The_DT association_NN of_IN
          atrial_NN fibrillation_NN with_IN mortality_NN as_IN a_DT time-dependent_JJ
          variable_NN was_VBD tested_VBN by_IN Cox_NNP non-proportional_JJ hazards_NNS
          regression_NN analysis_NN as_RB previously_RB described_VBD ._. [_NN 18_CD ]_NN
          Hierarchically_NNP well-formed_JJ models_NNS were_VBD used_VBN in_IN the_DT
          assessment_NN of_IN interaction_NN terms_NNS ._. [_NN 19_CD ]_NN Collinearity_NNP
          diagnostics_NNS were_VBD evaluated_VBN both_DT from_IN the_DT output_NN of_IN the_DT
          statistical_JJ procedures_NNS and_CC by_IN manual_JJ generation_NN of_IN models_NNS
          including_VBG only_RB one_CD of_IN several_JJ variables_NNS with_IN close_JJ
          relationships_NNS (_( for_IN example_NN ,_, congestive_JJ heart_NN failure_NN and_CC
          left_VBD ventricular_NN hypertrophy_NN ,_, which_WDT was_VBD assessed_VBN by_IN chest_NN
          X-_NNP ray_NN ,_, electrocardiogram_NN ,_, and_CC echocardiography_NN )_) ._.
          Propensity_NNP scores_NNS [_NN 20_CD 21_CD ]_NN have_VBP been_VBN used_VBN to_TO adjust_VB for_IN
          confounding_VBG in_IN baseline_NN medication_NN use_NN ._. Since_IN this_DT method_NN
          is_VBZ primarily_RB undertaken_VBN to_TO assess_VB uniformity_NN of_IN risk_NN
          among_IN strata_NN ,_, model_JJ fitting_NN was_VBD also_RB tested_VBN by_IN fitting_JJ
          models_NNS to_TO a_DT 70_CD %_NN random_JJ sample_NN of_IN the_DT study_NN population_NN ,_,
          and_CC then_RB running_VBG the_DT same_JJ model_NN for_IN the_DT remaining_VBG 30_CD %_NN of_IN
          the_DT population_NN to_TO test_VB for_IN agreement_NN ._.
        
      
      
        Results_NNS
        A_DT total_NN of_IN 4065_CD patients_NNS were_VBD included_VBN in_IN the_DT DMMS_NNP Wave_NNP
        2_CD cohort_NN ._. Of_IN these_DT ,_, 3621_CD patients_NNS had_VBD valid_JJ dates_NNS for_IN
        starting_VBG dialysis_NN in_IN 1996_CD ._. From_IN this_DT cohort_NN ,_, 3374_CD had_VBD
        sufficient_JJ information_NN to_TO calculate_VB follow-up_JJ times_NNS ._. During_IN
        the_DT time_NN of_IN the_DT study_NN period_NN ,_, 123_CD patients_NNS were_VBD
        hospitalized_VBN for_IN a_DT primary_JJ discharge_NN diagnosis_NN of_IN atrial_NN
        fibrillation_NN ,_, with_IN an_DT incidence_NN density_NN of_IN 12_CD ._. 5_LS /_NN 1000_CD person_NN
        years_NNS ._.
        Use_NN of_IN digoxin_NN and_CC particularly_RB levothyroxine_NN was_VBD common_JJ
        in_IN dialysis_NN patients_NNS ._. Among_IN other_JJ anti-arrhythmic_JJ agents_NNS ,_,
        only_RB amiodarone_NN was_VBD used_VBN by_IN more_JJR than_IN 10_CD patients_NNS at_IN
        baseline_NN ,_, and_CC so_RB is_VBZ the_DT only_RB other_JJ agent_NN reported_VBD ._. Among_IN
        the_DT study_NN population_NN ,_, cardioselective_JJ beta-blockers_JJ were_VBD
        used_VBN by_IN 14_CD ._. 6_CD %_NN of_IN patients_NNS hospitalized_VBN for_IN atrial_NN
        fibrillation_NN vs_NNS ._. 14_CD ._. 4_LS %_NN of_IN all_DT other_JJ patients_NNS ;_: digoxin_NN was_VBD
        used_VBN by_IN 12_CD %_NN of_IN patients_NNS hospitalized_VBN for_IN atrial_NN
        fibrillation_NN vs_NNS ._. 3_CD ._. 8_CD %_NN of_IN all_DT other_JJ patients_NNS ;_: and_CC coumadin_NN
        was_VBD used_VBN by_IN 8_CD ._. 1_CD %_NN of_IN patients_NNS hospitalized_VBN for_IN atrial_NN
        fibrillation_NN vs_NNS ._. 5_CD ._. 6_CD %_NN of_IN all_DT other_JJ patients_NNS ._.
        Characteristics_NNP of_IN the_DT study_NN population_NN ,_, including_VBG
        univariate_NN associations_NNS with_IN hospitalized_VBN atrial_NN
        fibrillation_NN ,_, are_VBP summarized_VBD in_IN Table_NNP 1_CD ._. Table_NNP 2_CD shows_VBZ the_DT
        percentage_NN of_IN patients_NNS who_WP were_VBD hospitalized_VBN for_IN atrial_NN
        fibrillation_NN by_IN risk_NN group_NN ._. As_IN shown_VBN ,_, there_EX were_VBD marked_VBN
        disparities_NNS by_IN age_NN ,_, blood_NN pressure_NN ,_, dialysis_NN modality_NN ,_, and_CC
        history_NN of_IN left_JJ ventricular_NN hypertrophy_NN ._.
        Table_NNP 3_CD shows_VBZ significant_JJ factors_NNS associated_VBN with_IN
        hospitalized_VBN atrial_NN fibrillation_NN in_IN multivariate_NN analysis_NN
        by_IN Cox_NNP Regression_NNP ._. Factors_NNP positively_RB associated_VBN with_IN
        atrial_NN fibrillation_NN were_VBD advanced_VBN age_NN (_( >_NN =_SYM 71_CD years_NNS vs_NNS ._.
        age_NN <_NN 48_CD years_NNS )_) ,_, hemodialysis_NNS (_( vs_NNS ._. peritoneal_JJ dialysis_NN )_) ,_,
        and_CC baseline_NN digoxin_NN use_NN ._. Pre-dialysis_NNP systolic_JJ blood_NN
        pressure_NN had_VBD a_DT "_'' U_NNP "_'' shaped_VBN association_NN with_IN atrial_NN
        fibrillation_NN ,_, with_IN highest_JJS risk_NN associated_VBN with_IN the_DT low_JJ and_CC
        high_JJ extremes_NNS of_IN blood_NN pressure_NN (_( Figure_NN 1_LS )_) ._. However_RB ,_,
        neither_DT pre-dialysis_JJ diastolic_JJ blood_NN pressure_NN nor_CC
        post-dialysis_JJ blood_NN pressure_NN were_VBD associated_VBN with_IN the_DT risk_NN
        of_IN atrial_NN fibrillation_NN ,_, nor_CC were_VBD serum_NN albumin_NN levels_NNS ._. No_DT
        medications_NNS except_IN digoxin_NN were_VBD independently_RB associated_VBN
        with_IN atrial_NN fibrillation_NN ._. There_EX were_VBD also_RB no_DT significant_JJ
        interactions_NNS between_IN terms_NNS ,_, specifically_RB between_IN
        medications_NNS ,_, laboratory_NN data_NNS or_CC dialysis_NN modality_NN in_IN
        patients_NNS with_IN preexisting_VBG coronary_JJ heart_NN disease_NN ._.
        There_EX were_VBD 1961_CD total_JJ deaths_NNS in_IN the_DT cohort_NN through_IN 6_CD
        November_NNP 2000_CD ._. Of_IN the_DT 123_CD patients_NNS hospitalized_VBN for_IN atrial_NN
        fibrillation_NN ,_, 90_CD died_VBD during_IN the_DT study_NN period_NN ._. Mean_VB
        follow-up_JJ was_VBD 2_CD ._. 92_CD Â±_NN 1_CD ._. 14_CD years_NNS ._. Unadjusted_NNP survival_NN after_IN
        atrial_NN fibrillation_NN and_CC for_IN the_DT entire_JJ cohort_NN is_VBZ also_RB shown_VBN
        in_IN Table_NNP 4_CD ._. Survival_NNP was_VBD significantly_RB worse_JJR after_IN atrial_NN
        fibrillation_NN in_IN Cox_NNP non-proportional_JJ hazards_NNS regression_NN
        analysis_NN ,_, adjusted_VBN hazard_NN ratio_NN for_IN mortality_NN ,_, 1_CD ._. 54_CD ,_, 95_CD %_NN
        confidence_NN interval_NN ,_, 1_CD ._. 19_CD -_: 1_CD ._. 99_CD ,_, p_NN =_SYM 0_CD ._. 001_CD ._. The_DT leading_VBG
        cause_NN of_IN death_NN among_IN patients_NNS hospitalized_VBN for_IN atrial_NN
        fibrillation_NN was_VBD unknown_JJ (_( 26_CD %_NN )_) ,_, followed_VBN by_IN cardiac_JJ arrest_NN
        of_IN unknown_JJ cause_NN (_( 19_CD %_NN )_) ,_, cardiac_JJ arrthymia_NN (_( 8_CD %_NN )_) ,_, acute_JJ
        myocardial_NN infarction_NN (_( 7_CD %_NN )_) ,_, atherosclerotic_JJ heart_NN disease_NN
        (_( 6_CD %_NN )_) ,_, cardiomyopathy_NN (_( 3_CD %_NN )_) and_CC stroke_NN (_( 3_CD %_NN )_) ._. Of_IN patients_NNS
        hospitalized_VBN for_IN atrial_NN fibrillation_NN ,_, the_DT most_RBS common_JJ
        secondary_JJ diagnosis_NN was_VBD hypertensive_JJ heart_NN disease_NN (_( 15_CD %_NN )_) ,_,
        followed_VBN by_IN congestive_JJ heart_NN failure_NN (_( 11_CD %_NN )_) ._.
        Table_NNP 5_CD shows_VBZ Cox_NNP Regression_NNP analysis_NN of_IN factors_NNS
        significantly_RB associated_VBN with_IN mortality_NN in_IN patients_NNS with_IN
        hospitalized_VBN atrial_NN fibrillation_NN ._. Only_RB two_CD factors_NNS ,_, the_DT
        baseline_NN use_NN of_IN coumadin_NN (_( Figure_NN 2_LS )_) and_CC higher_JJR systolic_JJ
        blood_NN pressure_NN ,_, were_VBD associated_VBN with_IN a_DT lower_JJR risk_NN of_IN
        mortality_NN after_IN hospitalization_NN for_IN atrial_NN fibrillation_NN ._. Of_IN
        note_NN ,_, calcium_NN channel_NN blockers_NNS ,_, specifically_RB
        non-dihyropyridine_JJ calcium_NN channel_NN blockers_NNS ,_, were_VBD not_RB
        significantly_RB associated_VBN with_IN mortality_NN in_IN patients_NNS with_IN
        atrial_NN fibrillation_NN ._. In_IN fact_NN ,_, the_DT hazard_NN ratio_NN for_IN
        mortality_NN of_IN patients_NNS with_IN atrial_NN fibrillation_NN using_VBG
        non-dihydropyridine_JJ calcium_NN channel_NN blockers_NNS was_VBD 1_CD ._. 85_CD ,_,
        although_IN the_DT p_NN value_NN was_VBD 0_CD ._. 21_CD and_CC 95_CD %_NN confidence_NN intervals_NNS
        were_VBD 0_CD ._. 69_CD -_: 4_CD ._. 94_CD ._. Dihydropyridine_NNP calcium_NN blockers_NNS ,_, as_RB well_RB
        as_IN ACE_NNP inhibitors_NNS and_CC aspirin_NN ,_, were_VBD also_RB not_RB significantly_RB
        associated_VBN with_IN mortality_NN in_IN patients_NNS with_IN atrial_NN
        fibrillation_NN ._. Because_IN use_NN of_IN coumadin_NN might_MD be_VB biased_VBN by_IN
        association_NN with_IN factors_NNS favorably_RB associated_VBN with_IN
        mortality_NN ,_, logistic_JJ regression_NN analysis_NN was_VBD performed_VBN to_TO
        assess_VB factors_NNS independently_RB associated_VBN with_IN use_NN of_IN
        coumadin_NN ._. However_RB ,_, only_RB three_CD factors_NNS were_VBD independently_RB
        associated_VBN with_IN the_DT use_NN of_IN coumadin_NN :_: left_VBD ventricular_NN
        hypertrophy_NN on_IN echocardiography_NN (_( adjusted_VBN odds_NNS ratio_NN ,_, 1_CD ._. 88_CD ,_,
        95_CD %_NN CI_NNP ,_, 1_CD ._. 10_CD -_: 3_CD ._. 20_CD ,_, p_NN =_SYM 0_CD ._. 02_CD )_) ;_: chronic_JJ obstructive_JJ lung_NN
        disease_NN (_( adjusted_VBN odds_NNS ratio_NN ,_, 1_CD ._. 98_CD ,_, 95_CD %_NN CI_NNP ,_, 1_CD ._. 05_CD -_: 3_CD ._. 74_CD )_) ;_: and_CC
        aspirin_NN use_NN (_( adjusted_VBN odds_NNS ratio_NN ,_, 0_CD ._. 31_CD ,_, 95_CD %_NN CI_NNP ,_, 0_CD ._. 14_CD -_: 0_CD ._. 67_CD ,_,
        p_NN =_SYM 0_CD ._. 002_CD )_) ._. When_WRB Cox_NNP regression_NN analysis_NN was_VBD performed_VBN
        limited_VBN to_TO patients_NNS who_WP had_VBD left_VBN ventricular_NN hypertrophy_NN ,_,
        chronic_JJ obstructive_JJ lung_NN disease_NN ,_, or_CC did_VBD not_RB use_VB aspirin_NN (_( N_NNP
        hospitalized_VBN for_IN atrial_NN fibrillation_NN =_SYM 87_CD )_) ,_, coumadin_NN use_NN
        was_VBD still_RB significantly_RB associated_VBN with_IN improved_VBN survival_NN ,_,
        adjusted_VBN hazard_NN ratio_NN ,_, 0_CD ._. 36_CD ,_, 95_CD %_NN CI_NNP ,_, 0_CD ._. 16_CD -_: 0_CD ._. 82_CD ,_, p_NN =_SYM 0_CD ._. 014_CD ._.
        Models_NNP were_VBD robust_JJ to_TO testing_NN on_IN random_JJ samples_NNS of_IN the_DT
        study_NN population_NN (_( 70_CD %_NN vs_NNS ._. the_DT remaining_VBG 30_CD %_NN )_) ._.
      
      
        Discussion_NNP
        In_IN agreement_NN with_IN some_DT previous_JJ studies_NNS in_IN the_DT general_JJ
        population_NN [_NN 1_CD ,_, 4_CD ]_NN and_CC preliminary_JJ reports_NNS from_IN the_DT USRDS_NNP ,_, [_NN
        22_CD ]_NN atrial_NN fibrillation_NN was_VBD associated_VBN with_IN increased_VBN
        mortality_NN among_IN chronic_JJ dialysis_NN patients_NNS ._. In_IN the_DT general_JJ
        population_NN ,_, cardiovascular_JJ events_NNS ,_, and_CC not_RB thromboembolic_JJ
        events_NNS ,_, are_VBP the_DT most_RBS common_JJ cause_NN of_IN death_NN after_IN atrial_NN
        fibrillation_NN ,_, [_NN 23_CD ]_NN in_IN agreement_NN with_IN the_DT findings_NNS of_IN the_DT
        present_JJ analysis_NN ._. However_RB ,_, it_PRP is_VBZ also_RB possible_JJ that_IN
        thromboembolic_JJ events_NNS could_MD have_VB been_VBN underdiagnosed_JJ due_NN to_TO
        a_DT low_JJ index_NN of_IN suspicion_NN for_IN thromboembolism_NN in_IN chronic_JJ
        dialysis_NN patients_NNS ,_, [_NN 24_CD 25_CD 26_CD ]_NN because_IN of_IN the_DT high_JJ number_NN
        of_IN deaths_NNS with_IN an_DT unknown_JJ cause_NN ,_, the_DT low_JJ rate_NN of_IN autopsies_NNS
        in_IN this_DT population_NN ,_, or_CC a_DT combination_NN of_IN these_DT factors_NNS ._.
        Vazquez_NNP et_CC al_NN [_NN 5_CD ]_NN provide_VB further_JJ evidence_NN that_IN causes_NNS of_IN
        death_NN may_MD underestimate_NN the_DT incidence_NN of_IN embolic_JJ events_NNS in_IN
        chronic_JJ dialysis_NN patients_NNS with_IN atrial_NN fibrillation_NN ._. They_PRP
        reported_VBD that_IN 35_CD %_NN of_IN chronic_JJ dialysis_NN patients_NNS with_IN atrial_NN
        fibrillation_NN suffered_VBD thromboembolic_JJ events_NNS at_IN one_CD year_NN of_IN
        followup_NN ._.
        Risk_NN factors_NNS for_IN atrial_NN fibrillation_NN in_IN chronic_JJ dialysis_NN
        patients_NNS were_VBD consistent_JJ with_IN established_VBN risk_NN factors_NNS [_NN 4_CD
        5_CD 27_CD ]_NN ,_, except_IN for_IN the_DT association_NN with_IN hemodialysis_NNS
        (_( compared_VBN with_IN those_DT on_IN peritoneal_JJ dialysis_NN )_) ._. In_IN addition_NN
        to_TO age_NN ,_, left_VBD ventricular_NN hypertrophy_NN is_VBZ also_RB a_DT
        well-established_JJ risk_NN factor_NN for_IN atrial_NN fibrillation_NN in_IN the_DT
        general_JJ population_NN ._. Many_JJ markers_NNS for_IN cardiovascular_JJ
        comorbidity_NN were_VBD associated_VBN with_IN atrial_NN fibrillation_NN in_IN
        univariate_NN analysis_NN (_( Table_NNP 1_LS )_) ,_, but_CC not_RB in_IN multivariate_NN
        analysis_NN (_( Table_NNP 3_LS )_) ._. While_IN the_DT efficacy_NN of_IN cardioversion_NN in_IN
        successful_JJ conversion_NN of_IN atrial_NN dysrythmias_NNS may_MD be_VB helpful_JJ
        in_IN some_DT settings_NNS ,_, it_PRP is_VBZ less_RBR useful_JJ than_IN the_DT duration_NN of_IN
        the_DT dysrythmia_NN in_IN patients_NNS with_IN atrial_NN fibrillation_NN ._. [_NN 28_CD ]_NN
        However_RB ,_, it_PRP has_VBZ never_RB been_VBN established_VBN whether_IN the_DT same_JJ
        guidelines_NNS apply_VBP to_TO dialysis_NN patients_NNS ._. The_DT present_JJ study_NN
        could_MD not_RB assess_VB whether_IN cardiac_JJ enlargement_NN affected_VBD the_DT
        success_NN rate_NN of_IN cardioversion_NN in_IN dialysis_NN patients_NNS
        hospitalized_VBN for_IN atrial_NN fibrillation_NN ._.
        Pre-dialysis_NNP systolic_JJ blood_NN pressure_NN exhibited_VBN a_DT "_'' U_NNP "_''
        shaped_VBN relationship_NN with_IN the_DT risk_NN of_IN atrial_NN fibrillation_NN ,_,
        which_WDT is_VBZ similar_JJ to_TO the_DT "_'' U_NNP "_'' shaped_VBN relationship_NN of_IN blood_NN
        pressure_NN with_IN mortality_NN and_CC other_JJ cardiovascular_JJ events_NNS in_IN
        chronic_JJ dialysis_NN patients_NNS ._. Recent_JJ reports_NNS have_VBP indicated_VBN
        that_DT pulse_NN pressure_NN is_VBZ a_DT more_RBR predictive_JJ indicator_NN of_IN
        cardiovascular_JJ events_NNS in_IN dialysis_NN patients_NNS than_IN either_DT
        systolic_JJ or_CC diastolic_JJ blood_NN pressure_NN separately_RB ._. [_NN 29_CD ]_NN
        However_RB ,_, pulse_NN pressure_NN was_VBD not_RB independently_RB associated_VBN
        with_IN atrial_NN fibrillation_NN in_IN our_PRP$ analysis_NN ._.
        Hemodialysis_NNP was_VBD associated_VBN with_IN a_DT significantly_RB higher_JJR
        risk_NN of_IN atrial_NN fibrillation_NN than_IN peritoneal_JJ dialysis_NN in_IN the_DT
        present_JJ study_NN ._. It_PRP is_VBZ possible_JJ this_DT association_NN represents_VBZ
        bias_NN ,_, since_IN hemodialysis_NNS patients_NNS present_JJ for_IN medical_JJ care_NN
        much_RB more_RBR frequently_RB than_IN peritoneal_JJ dialysis_NN patients_NNS ,_, and_CC
        asymptomatic_JJ atrial_NN fibrillation_NN is_VBZ more_RBR readily_RB detected_VBD ._.
        However_RB ,_, there_EX are_VBP legitimate_JJ reasons_NNS why_WRB atrial_NN
        fibrillation_NN might_MD occur_VB more_RBR frequently_RB on_IN hemodialysis_NNS
        than_IN on_IN peritoneal_JJ dialysis_NN ._. First_LS ,_, Foley_NNP et_CC al_NN
        demonstrated_VBN that_IN progressive_JJ cardiac_JJ enlargement_NN was_VBD more_RBR
        frequent_JJ in_IN hemodialysis_NNS patients_NNS than_IN peritoneal_JJ dialysis_NN
        patients_NNS ,_, [_NN 2_CD ]_NN although_IN these_DT findings_NNS were_VBD not_RB replicated_VBN
        in_IN a_DT Japanese_JJ study_NN ._. [_NN 30_CD ]_NN Other_JJ investigators_NNS have_VBP
        confirmed_VBN that_IN LVH_NNP progresses_VBZ despite_IN adequate_JJ blood_NN
        pressure_NN control_NN in_IN hemodialysis_NNS patients_NNS ._. [_NN 31_CD ]_NN Also_RB ,_,
        hospitalized_VBN congestive_JJ heart_NN failure_NN is_VBZ more_RBR common_JJ in_IN
        hemodialysis_NNS than_IN peritoneal_JJ dialysis_NN patients_NNS ,_, especially_RB
        for_IN those_DT on_IN the_DT renal_JJ transplant_NN waiting_VBG list_NN ._. [_NN 32_CD ]_NN The_DT
        typical_JJ regimen_NN for_IN hemodialysis_NNS is_VBZ likely_JJ far_RB less_RBR
        physiologic_JJ than_IN peritoneal_JJ dialysis_NN ._. Residual_NNP renal_JJ
        function_NN may_MD also_RB be_VB preserved_VBN longer_JJR in_IN patients_NNS on_IN
        peritoneal_JJ dialysis_NN ,_, although_IN this_DT is_VBZ controversial_JJ ._. [_NN 33_CD
        34_CD ]_NN Some_DT or_CC all_DT of_IN these_DT factors_NNS may_MD therefore_RB mediate_VB the_DT
        higher_JJR risk_NN of_IN atrial_NN fibrillation_NN associated_VBN with_IN
        hemodialysis_NNS ._.
        The_DT effectiveness_NN of_IN coumadin_NN for_IN atrial_NN fibrillation_NN in_IN
        chronic_JJ dialysis_NN patients_NNS has_VBZ not_RB been_VBN assessed_VBN previously_RB ._.
        In_IN fact_NN ,_, previous_JJ reports_NNS considered_VBN chronic_JJ renal_JJ failure_NN
        a_DT contraindication_NN to_TO the_DT use_NN of_IN anticoagulation_NN in_IN atrial_NN
        fibrillation_NN ._. [_NN 35_CD ]_NN Wiesholzer_NNP et_CC al_NN concluded_VBD that_IN
        non-rheumatic_JJ atrial_NN fibrillation_NN was_VBD not_RB an_DT independent_JJ
        risk_NN factor_NN for_IN stroke_NN in_IN dialysis_NN patients_NNS ._. [_NN 36_CD ]_NN
        Therefore_RB ,_, Figure_NN 2_CD suggests_VBZ several_JJ possibilities_NNS ._. First_LS ,_,
        although_IN the_DT clinical_JJ indications_NNS for_IN coumadin_NN use_NN in_IN this_DT
        cohort_NN were_VBD unknown_JJ ,_, coumadin_NN is_VBZ often_RB given_VBN for_IN a_DT limited_JJ
        period_NN of_IN time_NN [_NN 31_CD ]_NN ,_, after_IN which_WDT it_PRP is_VBZ often_RB
        discontinued_VBN ,_, in_IN the_DT absence_NN of_IN known_VBN predisposing_VBG factors_NNS ._.
        Therefore_RB ,_, patients_NNS who_WP were_VBD using_VBG coumadin_NN at_IN the_DT time_NN of_IN
        the_DT study_NN assessment_NN and_CC later_RB discontinued_VBN it_PRP might_MD not_RB
        have_VB been_VBN taking_VBG coumadin_NN at_IN the_DT time_NN they_PRP were_VBD
        hospitalized_VBN for_IN atrial_NN fibrillation_NN ,_, negating_VBG a_DT possible_JJ
        beneficial_JJ association_NN of_IN coumadin_NN with_IN mortality_NN after_IN
        hospitalization_NN for_IN atrial_NN fibrillation_NN ._. Another_DT
        possibility_NN is_VBZ that_IN many_JJ patients_NNS not_RB taking_VBG coumadin_NN at_IN
        baseline_NN may_MD have_VB later_RB been_VBN treated_VBN with_IN coumadin_NN after_IN
        hospitalization_NN for_IN atrial_NN fibrillation_NN ._. Given_VBN the_DT growing_VBG
        evidence_NN that_IN dialysis_NN patients_NNS in_IN the_DT modern_JJ era_NN may_MD
        actually_RB be_VB hypercoagulable_JJ ,_, primarily_RB due_JJ to_TO defects_NNS of_IN
        the_DT fibrinolytic_JJ system_NN ,_, [_NN 25_CD 37_CD 38_CD ]_NN clinical_JJ trials_NNS of_IN
        the_DT use_NN of_IN anticoagulation_NN in_IN atrial_NN fibrillation_NN and_CC
        thromboembolic_JJ disorders_NNS are_VBP warranted_VBN ._. Of_IN note_NN ,_, baseline_NN
        coumadin_NN use_NN ,_, in_IN contrast_NN to_TO digoxin_NN use_NN ,_, was_VBD not_RB
        associated_VBN with_IN hospitalization_NN for_IN atrial_NN fibrillation_NN and_CC
        therefore_RB presumably_RB was_VBD not_RB a_DT marker_NN for_IN patients_NNS with_IN
        pre-existing_JJ atrial_NN fibrillation_NN ._.
        The_DT decision_NN to_TO use_VB coumadin_NN in_IN patients_NNS with_IN atrial_NN
        fibrillation_NN in_IN whom_WP NSR_NNP cannot_NN be_VB established_VBN is_VBZ based_VBN on_IN
        an_DT assessment_NN of_IN both_DT their_PRP$ risk_NN of_IN serious_JJ bleeding_NN and_CC
        their_PRP$ risk_NN of_IN stroke_NN ._. Coumadin_NNP therapy_NN has_VBZ been_VBN associated_VBN
        with_IN improved_VBN survival_NN in_IN patients_NNS with_IN reduced_VBN LV_NNP systolic_JJ
        dysfunction_NN in_IN the_DT absence_NN of_IN dysrythmias_NNS as_IN well_RB ,_,
        primarily_RB through_IN reduction_NN in_IN cardiovascular_JJ events_NNS rather_RB
        than_IN reduction_NN of_IN thromboembolic_JJ events_NNS ._. [_NN 39_CD ]_NN This_DT may_MD be_VB
        one_CD explanation_NN for_IN the_DT association_NN of_IN coumadin_NN use_NN with_IN
        reduced_VBN mortality_NN in_IN chronic_JJ dialysis_NN patients_NNS hospitalized_VBN
        for_IN atrial_NN fibrillation_NN in_IN the_DT present_JJ study_NN ._.
      
      
        Study_NN limitations_NNS
        The_DT present_JJ study_NN was_VBD observational_NN and_CC not_RB randomized_JJ ,_,
        and_CC therefore_RB associations_NNS should_MD not_RB be_VB construed_VBN as_IN
        causative_JJ ._. The_DT study_NN is_VBZ a_DT random_JJ sample_NN of_IN all_DT hemodialysis_NNS
        patients_NNS ,_, not_RB the_DT total_JJ population_NN ,_, although_IN the_DT peritoneal_JJ
        dialysis_NN population_NN was_VBD almost_RB fully_RB captured_VBN ._. We_PRP did_VBD not_RB
        have_VB access_NN to_TO information_NN on_IN treatment_NN or_CC conversion_NN to_TO
        NSR_NNP in_IN patients_NNS who_WP were_VBD hospitalized_VBN for_IN atrial_NN
        fibrillation_NN ,_, nor_CC did_VBD we_PRP have_VB information_NN on_IN the_DT type_NN of_IN
        atrial_NN fibrillation_NN for_IN which_WDT patients_NNS presented_VBN and_CC how_WRB it_PRP
        was_VBD classified_VBN within_IN ACC_NNP /_NN AHA_NNP /_NN ESC_NNP guidelines_NNS ._. [_NN 40_CD ]_NN We_PRP did_VBD
        not_RB have_VB access_NN to_TO information_NN on_IN which_WDT patients_NNS had_VBD
        self-limited_JJ episodes_NNS of_IN atrial_NN fibrillation_NN vs_NNS ._. those_DT who_WP
        had_VBD persistent_JJ atrial_NN fibrillation_NN ,_, nor_CC the_DT duration_NN or_CC
        presence_NN of_IN atrial_NN fibrillation_NN prior_RB to_TO hospitalization_NN or_CC
        the_DT study_NN start_NN ._. We_PRP did_VBD not_RB have_VB information_NN on_IN left_JJ atrial_NN
        size_NN other_JJ than_IN the_DT presence_NN of_IN LVH_NNP on_IN echocardiography_NN ._. We_PRP
        also_RB did_VBD not_RB have_VB information_NN on_IN thyroid_NN functions_NNS (_( other_JJ
        than_IN baseline_NN use_NN of_IN thyroxine_NN )_) ,_, alcohol_NN use_NN ,_, or_CC
        pre-existing_JJ atrial_NN dysrythmias_NNS ._. Information_NN bias_NN could_MD
        have_VB arisen_VBN due_JJ to_TO mistakes_NNS in_IN coding_VBG or_CC spelling_VBG ,_,
        especially_RB for_IN medications_NNS ._. We_PRP were_VBD unable_JJ to_TO follow_VB
        changes_NNS in_IN variables_NNS over_IN time_NN ._. Therefore_RB ,_, we_PRP could_MD not_RB
        follow_VB changes_NNS in_IN blood_NN pressure_NN ,_, laboratory_NN values_NNS ,_,
        dialysis_NN adequacy_NN ,_, or_CC medications_NNS ._. We_PRP could_MD not_RB assess_VB
        other_JJ factors_NNS that_WDT have_VBP shown_VBN to_TO be_VB associated_VBN with_IN atrial_NN
        fibrillation_NN ,_, such_JJ as_IN hypokalemia_NN or_CC calcified_JJ
        aortic_JJ /_NN mitral_NN valves_NNS ,_, [_NN 41_CD ]_NN although_IN there_EX are_VBP many_JJ
        similarities_NNS between_IN the_DT risk_NN factors_NNS for_IN valvular_NN heart_NN
        disease_NN and_CC atrial_NN fibrillation_NN in_IN chronic_JJ dialysis_NN
        patients_NNS ._. [_NN 42_CD ]_NN Our_PRP$ use_NN of_IN atrial_NN fibrillation_NN as_IN an_DT
        outcome_NN variable_JJ required_VBN survival_NN to_TO reach_VB
        hospitalization_NN ,_, and_CC thus_RB sudden_JJ death_NN was_VBD not_RB considered_VBN
        as_IN an_DT outcome_NN ._. However_RB ,_, causes_NNS of_IN death_NN ,_, especially_RB if_IN not_RB
        verified_VBN by_IN autopsy_NN ,_, are_VBP also_RB of_IN questionable_JJ validity_NN in_IN
        comparison_NN to_TO the_DT rates_NNS of_IN total_JJ mortality_NN ._. [_NN 43_CD ]_NN
        In_IN summary_NN ,_, the_DT present_JJ observational_NN ,_, non-randomized_JJ
        study_NN confirms_VBZ the_DT high_JJ incidence_NN and_CC mortality_NN of_IN atrial_NN
        fibrillation_NN in_IN chronic_JJ dialysis_NN patients_NNS ._. Traditional_JJ risk_NN
        factors_NNS for_IN atrial_NN fibrillation_NN such_JJ ,_, as_IN older_JJR age_NN ,_, were_VBD
        confirmed_VBN ._. Hemodialysis_NNP ,_, possibly_RB due_JJ to_TO a_DT greater_JJR
        frequency_NN of_IN progressive_JJ cardiac_JJ enlargement_NN or_CC more_RBR
        frequent_JJ observation_NN ,_, was_VBD also_RB identified_VBN as_IN a_DT risk_NN factor_NN
        for_IN atrial_NN fibrillation_NN ._. Of_IN the_DT greatest_JJS potential_JJ
        importance_NN ,_, the_DT use_NN of_IN coumadin_NN at_IN the_DT start_NN of_IN the_DT study_NN
        was_VBD associated_VBN with_IN lower_JJR mortality_NN in_IN patients_NNS later_RB
        hospitalized_VBN for_IN atrial_NN fibrillation_NN ._. These_DT findings_NNS should_MD
        be_VB confirmed_VBN in_IN clinical_JJ trials_NNS ._.
      
      
        Author_NN '_'' contributions_NNS
        KCA_NNP conceived_VBD the_DT original_JJ concept_NN ,_, performed_VBD the_DT
        analyses_NNS ,_, and_CC wrote_VBD most_JJS of_IN the_DT manuscript_NN
        FCT_NNP collaborated_VBD in_IN the_DT manuscript_NN and_CC was_VBD instrumental_JJ
        in_IN the_DT initial_JJ preparation_NN of_IN DMMS_NNP 2_CD files_NNS for_IN analysis_NN ,_,
        especially_RB medications_NNS
        AJT_NNP collaborated_VBD in_IN the_DT manuscript_NN providing_VBG background_NN
        on_IN atrial_NN fibrillation_NN and_CC its_PRP$ role_NN in_IN chronic_JJ renal_JJ
        failure_NN ._.
        LYA_NNP ,_, as_IN Project_NNP Director_NNP for_IN the_DT NIDDK_NNP ,_, is_VBZ a_DT world_NN
        expert_NN on_IN the_DT USRDS_NNP and_CC was_VBD instrumental_JJ in_IN the_DT
        interpretation_NN of_IN USRDS_NNP files_NNS ._.
      
      
        Competing_VBG interest_NN
        None_NN declared_VBD
      
    
  
